Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Vertex Pharmaceuticals Incorporated

< Previous 1 2 3 4 5 6 Next >

Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain

March 31, 2022

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene

March 26, 2022

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease

March 22, 2022

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Reports Fourth Quarter 2021 and Full Year Financial Results

January 26, 2022

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex to Announce Fourth Quarter 2021 Financial Results on January 26

January 18, 2022

From Vertex Pharmaceuticals Incorporated

Via Business Wire

European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years

January 11, 2022

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10

January 04, 2022

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis

December 01, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene

November 19, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11

November 12, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Reports Third-Quarter 2021 Financial Results

November 02, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex to Announce Third-Quarter 2021 Financial Results on November 2

October 22, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)

October 19, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes

October 18, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th

September 13, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis

August 26, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer

August 04, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Reports Second-Quarter 2021 Financial Results

July 29, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis

July 28, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain

July 19, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex to Announce Second-Quarter 2021 Financial Results on July 29

July 16, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients

June 28, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis

June 25, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation

June 18, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting

June 11, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency

June 10, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations

June 09, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations

June 09, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13

May 10, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Reports First-Quarter 2021 Financial Results

April 29, 2021

From Vertex Pharmaceuticals Incorporated

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Vertex Pharmaceuticals Incorporated

Starting at $3.75/week.

Subscribe Today